Xtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above Two Hundred Day Moving Average of $0.00

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.65. Xtant Medical shares last traded at $0.63, with a volume of 31,056 shares.

Analysts Set New Price Targets

Separately, BTIG Research boosted their price objective on shares of Xtant Medical from $2.00 to $3.00 and gave the stock a “buy” rating in a research note on Thursday, May 16th.

Xtant Medical Stock Down 3.9 %

The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.98 and a current ratio of 2.34. The firm has a market capitalization of $81.42 million, a price-to-earnings ratio of -62.50 and a beta of 0.33.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $27.87 million for the quarter. Xtant Medical had a negative return on equity of 3.60% and a negative net margin of 1.64%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. acquired a new stake in shares of Xtant Medical in the 3rd quarter valued at approximately $516,000. Juniper Investment Company LLC acquired a new stake in shares of Xtant Medical in the 1st quarter valued at approximately $408,000. Finally, Vanguard Group Inc. raised its position in shares of Xtant Medical by 3.2% in the 1st quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock valued at $1,812,000 after acquiring an additional 48,319 shares during the period. 69.33% of the stock is currently owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.